Iconic Therapeutics fetches $40 mln Series C

By Iris Dorbian — 4 weeks ago

Iconic Therapeutics, a biopharmaceutical company focused on serious eye disorders, has raised $40 million in Series C funding. The investors included HBM Healthcare Investments, Cormorant Asset Management, Osage University Partners, MPM Capital, H.I.G. Capital and Lundbeckfund Ventures.

Continue

MPM Capital adds new MD to team

By Iris Dorbian — 5 months ago

MPM Capital has named Dr. Mitchell H. Finer as managing director. Previously, Finer, who also serves on the board of MPM portfolio company Semma Therapeutics Inc, worked at bluebird.

Continue

Syndax Pharmaceuticals racks up $80 mln Series C

By Iris Dorbian — 6 months ago

Waltham, Massachusetts-based Syndax Pharmaceuticals Inc, a biopharmaceutical company focused on treating cancer, has closed $80 million in Series C funding. Fidelity Management & Research Company and Delos Capital Fund LP led the round with participation from other investors that included EcoR1 Capital, OrbiMed, Jennison Associates (on behalf of certain clients), Tavistock Life Sciences, Arrowpoint Partners, Cormorant Asset Management, BioMed Ventures, Domain Associates, MPM Capital, RusnanoMedInvest and Forward Ventures.

Continue

Rhythm Metabolic racks up $40 mln Series A

By Iris Dorbian — 6 months ago

Boston-based Rhythm Metabolic, a subsidiary of Rhythm, has closed $40 million in Series A funding. The investors included OrbiMed, Deerfield Management, Wellington Management Company, MPM Capital, New Enterprise Associates, Third Rock Ventures, Pfizer Ventures and Ipsen. In conjunction with the funding, Jonathan Silverstein of OrbiMed has been appointed to Rhythm Metabolic’s board of directors. Rhythm Metabolic is focused on treating obesity caused by genetic deficiencies.

Continue

Morrison named MD at MPM Capital

By Luisa Beltran — 8 months ago

MPM Capital said Monday that it named Briggs W. Morrison M.D. to the position of Managing Director. Dr. Morrison was recently appointed CEO of Syndax Pharmaceuticals Inc., an MPM portfolio company.

Continue

Cagnoni named MPM Capital managing director

By Luisa Beltran — 9 months ago

MPM Capital said Wednesday it named Pablo Cagnoni, M.D., a Managing Director. Cagnoni is the former President of Onyx Pharmaceuticals. He is also co-founder of MPM portfolio company, Vesuvius, where he is taking on the role of President and CEO.

Continue

MPM Capital adds new MD to team

By Iris Dorbian — 10 months ago

MPM Capital named Gregory Sieczkiewicz as managing director and chief counsel, intellectual property. The appointment is effective immediately. Previously, Sieczkiewicz worked at Flagship Ventures where he served as vice president of intellectual property.

Continue

Semma Therapeutics nets $44 mln

By Iris Dorbian — 11 months ago

Cambridge, Massachusetts-based Semma Therapeutics, a developer of cell therapy for Type 1 diabetes, has secured $44 million in Series A funding. MPM Capital led the round with participation from Fidelity Biosciences, ARCH Venture Partners and Medtronic. Also, the company has named Stephen Oesterle, senior vice president for medicine and technology at Medtronic, as a board observer.

Continue

Clinical Ink racks up venture funding, also merges with CentrosHealth

By Iris Dorbian — 11 months ago

Clinical Ink, a provider of eSource solutions for clinical trials has raised an undisclosed amount of funding. The investors in this round included MPM Capital, F2 Ventures and FCA Venture Partners. In conjunction with the funding, MPM Capital and F2 Ventures will take seats on Clinical Ink’s board of directors. Also, Clinical Ink is merging with CentrosHealth, a provider of mobile apps for clinical trial patient engagement and electronic patient reported outcomes. No financial terms were disclosed. CentrosHealth was founded by MPM Capital.

Continue

Baeuerle joins MPM Capital as MD

By Luisa Beltran — 11 months ago

MPM Capital said Wednesday it named Dr. Patrick A. Baeuerle a Managing Director effective April 1. Baeuerle most recently was Vice President, Research, and General Manager, Amgen Research (Munich) GmbH.

Continue

Vascular Pharmaceuticals snares $9 mln

By Iris Dorbian — 11 months ago

Research Triangle Park, North Carolina-based Vascular Pharmaceuticals Inc, a diabetes-focused pharmaceutical company, has secured $9 million in Series A funding. The investors included Lumira Capital, Intersouth Partners and MPM Capital. In addition to the funding, Dr. Beni Rovinski, managing director of Lumira Capital, has been added to VPI’s board of directors.

Continue

Chiasma snags $70 mln Series E

By Iris Dorbian — 11 months ago

Chiasma Inc has received $70 million in Series E financing. The investors included Rock Springs Capital, Sofinnova Ventures, MPM Capital, F2 Capital, 7 Med Health Ventures, Abingworth and ARCH Venture Partners. Headquartered in Newton, Massachusetts and Jerusalem, Chiasma is a biopharmaceutical firm focused on treating acromegaly.

Continue

VC-backed Raze Therapeutics names new VP

By Iris Dorbian — 1 year ago

Raze Therapeutics has hired Dr. Mikel Moyer as vice president of molecular discovery. The appointment becomes effective November 1. Based in Cambridge, Mass., Raze Therapeutics is a biotech firm focused on developing new cancer drugs. Its backers include Atlas Venture, MPM Capital, MS Ventures, Partners Innovation Fund, Astellas Venture Management and Novartis.

Continue

VC-backed Rhythm files for IPO

By Iris Dorbian — 1 year ago

Rhythm has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. Citigroup and Cowen and Company are serving as the lead underwriters. Based in Boston, Rhythm is a biopharmaceutical firm that focuses on treating metabolic disorders. Its backers include MPM Capital, New Enterprise Associates, Third Rock Ventures, Ipsen and Pfizer Ventures.

Continue